Nanjing Well Pharmaceutical Group Co (SHSE:603351) Capex-to-Operating-Income : 0.43 (As of Mar. 2025)

Nanjing Well Pharmaceutical Group Co Capex-to-Operating-Income Chart

Nanjing Well Pharmaceutical Group Co Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Capex-to-Operating-Income		Get a 7-Day Free Trial					2.47	1.83	1.93	0.53	0.28

Nanjing Well Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Capex-to-Operating-Income	Get a 7-Day Free Trial															0.32	0.27	0.44	0.16	0.43

Competitive Comparison of Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income falls into.

Nanjing Well Pharmaceutical Group Co Capex-to-Operating-Income Calculation

Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Well Pharmaceutical Group Co  (SHSE:603351) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Nanjing Well Pharmaceutical Group Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Nanjing Well Pharmaceutical Group Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Well Pharmaceutical Group Co Business Description